Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Kopran Ltd

₹ 145-0.72%
16 Jan – close price
🔗kopran.com•BSE: 524280•NSE: KOPRAN
Market Cap₹ 701 Cr.
Current Price₹ 145
High / Low₹ 216
Stock P/E45.1
Book Value₹ 86.3
Dividend Yield2.07 %
ROCE8.63 %
ROE6.33 %
Face Value₹ 10.0
Sales₹ 242 Cr.
OPM10.6 %
Mar Cap₹ 701 Cr.

ABOUT

Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.

KEY POINTS

Business Verticals1. API Vertical:WOS Kopran Research Laboratories operates the API vertical.[1]The co. undertakes development, manufacturing, and sale of diverse Active Pharmaceutical Ingredients and Advanced Intermediates. It is one of the leaders in Atenolol and has 26 commercialised products[2][3]

Also present in buckets:
Asset Base ExpansionJv Partnerships AcquisitionsCredit Rating UpdatesCredit Rating UpdatesRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1668.9034.69400460.330.963124.952.5614478.318.9320.2154964.0130.1211543.963117.955.1512.970.07
2.Divi's Lab.6236.0066.61165513.660.48689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.7413.530.01
3.Torrent Pharma.4018.2062.75135955.090.80591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.1013.260.33
4.Cipla1397.5020.75112878.160.931353.373.737589.447.6422.7228349.5725.405441.141351.173.4314.720.01
5.Lupin2177.9023.0199527.000.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.0712.410.32
6.Dr Reddy's Labs1175.5017.0098114.930.681336.807.288828.309.8322.6934310.0024.645772.201347.102.7212.950.16
7.Mankind Pharma2175.4051.3789821.630.05520.18-22.003697.1620.7715.9813545.6724.121748.55511.515.878.890.55
8.Kopran145.1245.11701.062.07-3.99-160.4542.39-42.358.63241.6010.5815.54-3.991.685.080.11
–Median: 149 Co.392.630.01767.160.1213.9610.46161.7610.5814.89603.8515.9345.2614.123.138.560.21

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
53.6267.9680.2365.8698.6482.3390.6249.6173.5371.9475.9451.3342.39
Expenses
47.7261.8672.8665.0489.9470.2775.2844.3363.8460.5463.6546.2645.59
Operating Profit
5.906.107.370.828.7012.0615.345.289.6911.4012.295.07-3.20
Other Income
14.741.162.071.485.791.298.152.121.120.751.921.800.32
Profit before tax
18.915.427.510.2312.5911.1620.555.518.759.8311.714.61-4.87
Tax %
5.39%25.46%26.50%30.43%15.25%23.75%25.50%23.05%24.57%24.62%26.56%23.64%-18.07%
Net Profit
17.894.045.520.1510.668.5115.314.256.607.418.603.52-3.99
EPS in Rs
3.710.841.140.032.211.773.180.881.371.541.780.73-0.83

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
302326187182154197179223205273337271242
Expenses
264294162164145174156193189245301232216
Operating Profit
3832251792323301528373926
Other Income
66-09832108161765
Interest
14131010756433444
Depreciation
121033333444555
Profit before tax
1715111371716331637453621
Net Profit
171511851311231231352716
EPS in Rs
4.363.772.641.971.093.002.595.432.446.487.195.573.22
Dividend Payout %
0%0%0%0%0%0%0%55%123%46%42%54%–

Compounded Sales Growth

10 Years:-2%
5 Years:9%
3 Years:10%
TTM:-18%

Compounded Profit Growth

10 Years:6%
5 Years:19%
3 Years:32%
TTM:-55%

Stock Price CAGR

10 Years:10%
5 Years:3%
3 Years:1%
1 Year:-27%

Return on Equity

10 Years:6%
5 Years:7%
3 Years:8%
Last Year:6%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
39414343434343434848484848
Reserves
98136145158162175186204331347369383368
Borrowings
137464256525046163728234546
Other Liabilities
55514954425052614882717064
Total Liabilities
329275279311300319327324464506511546526
Fixed Assets
103333539384243474647526174
Gross Block
272.9178.0482.5742.6844.7151.4656.0064.6067.6373.1782.4696.67–
Accumulated Depreciation
170.2444.5847.593.346.569.5813.0517.1621.4125.8230.4435.22–
CWIP
1004877334576
Investments
746156157157158158159259260261263264
Other Assets
2191958811097112119115155195193215181
Total Assets
329275279311300319327324464506511546526

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
25319412121049-38173523
Cash from Investing Activity
-9-10-4-9-2-41-9-10010-6-15
Cash from Financing Activity
7-43-155-11-7-11-40138-26-246
Net Cash Flow
0-00-0-0-000-01514

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
663338774883868110611295124
Inventory Days
10424908411978149731199878129
Days Payable
69631141201151011141068512882108
Cash Conversion Cycle
100-614415260121481398291145
Working Capital Days
47124414649595964129116104114
ROCE %
11%11%10%10%5%9%8%14%6%9%11%9%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters
44.29%44.29%44.49%44.49%44.49%44.49%44.49%44.49%44.45%44.42%44.43%44.43%44.43%
FIIs
0.34%0.41%0.34%0.39%0.48%0.84%0.68%1.31%0.86%1.11%0.76%0.60%0.36%
DIIs
0.14%0.14%0.14%0.35%0.14%1.20%0.14%0.22%0.00%0.00%0.00%0.00%0.00%
Public
55.22%55.15%55.03%54.78%54.88%53.47%54.68%53.98%54.68%54.45%54.81%54.99%55.21%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Kopran Merger Update: NCLT Directs Shareholder & Creditor Meetings

10th April 2026, 10:08 pm

Kopran Clarifies Stock Price Rise is Market Driven, No Material Information Withheld

10th April 2026, 5:51 pm

Kopran Confirms SEBI Dematerialization Compliance for Q4 FY26

9th April 2026, 8:00 pm

Kopran Limited Confirms Market-Driven Volume Surge to BSE

8th April 2026, 6:13 pm

Kopran Announces Trading Window Closure for Financial Results

24th March 2026, 2:21 pm

Published by Other Websites

External media mentions & references

India Braces for Q3 Earnings Blitz: 230+ Firms Set to Reveal Results

18th January 2026, 8:01 pm

63 Indian Companies Turn Ex-Dividend Today, Investors Notified of Eligibility Cut-off

4th September 2025, 7:42 am

Multiple Companies Set to Trade Ex-Dividend Next Week

31st August 2025, 6:02 am

Kopran Ltd: Promoter Group to Increase Stake by 4.18% via Inter-se Transfer to Resolve Family Disputes

25th August 2025, 1:58 pm

Kopran Ltd. Server Data Breached; Company Probes Cyber Incident

Documents

Announcements

Board Meeting Intimation for Results Of Q3 FY 2025-26

13 Jan - Board meeting Jan 22, 2026 to approve unaudited standalone and consolidated Q3 results for quarter ended Dec 31, 2025.

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

8 Jan - Certificate confirming compliance with SEBI Regulation 74(5) for quarter ended December 31, 2025 issued by Registrar Bigshare.

Announcement under Regulation 30 (LODR)-Credit Rating

1 Jan - CRISIL reaffirmed Kopran and subsidiary ratings to BBB+/A2 (watch developing); facilities Rs69.31Cr and Rs124.75Cr.

Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

26 Dec - Revised Regulation 29 disclosures: promoter inter-se transfers on Sept 5 and 12, 2025; small stake changes (0.07%-0.56%).

Closure of Trading Window

23 Dec - Trading window closed Jan 01, 2026 until 48 hours after Q3 (ended Dec 31, 2025) unaudited results declaration.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2012

(from nse)

Financial Year 2012

(from bse)

Credit Ratings

Rating update

24 Dec from crisil

Rating update

26 Sep 2025 from crisil

Rating update

30 Jun 2025 from crisil

Rating update

1 Apr 2025 from crisil

Rating update

3 Sep 2024 from crisil

Rating update

5 Sep 2023 from crisil

Concalls

Nov 2025

PPT

Nov 2025

PPT

Jul 2025

PPT

May 2025

PPT

Mar 2025

Transcript

Feb 2025

Transcript

Feb 2025

TranscriptPPT

Nov 2024

TranscriptPPTRecording

Aug 2024

Transcript

Aug 2024

TranscriptPPT

May 2024

TranscriptPPT

Feb 2024

TranscriptPPT

Feb 2024

PPT

Nov 2023

TranscriptPPT

May 2022

PPT

Nov 2021

PPT

Jun 2021

PPT

Feb 2021

PPT

Nov 2020

PPT

Stock Analysis

Description

Kopran Limited is an integrated pharmaceutical company engaged in the manufacturing and global supply of formulations and Active Pharmaceutical Ingredients (APIs).

Key Growth Triggers

Strategic focus remains on R&D and global market expansion.

Order Book

Currently no data available for Order Book.

Key Red Flags

CRISIL rating of BBB+/A2 'watch developing' signals potential rating changes. Recent consolidated net losses and YoY revenue decline in Q2 FY26 highlight financial challenges.

Key Dates To Watch

Board meeting on January 22, 2026, to approve Q3 FY26 financial results.

Corporate Announcements

10th Apr 26
Impact Rating: 9
The NCLT, Mumbai Bench, issued an order on April 09, 2026, directing Kopran Limited to hold meetings for shareholders and creditors concerning the merger with Kopran Laboratories Limited.
10th Apr 26
Impact Rating: 3
Kopran Limited clarified to BSE that its recent share price surge is purely market driven, assuring that all required disclosures have been made and no material information was withheld.
9th Apr 26
Impact Rating: 4
Kopran Limited has confirmed compliance with SEBI Regulation 74(5) for the quarter ending March 31, 2026, based on verification from its Registrar and Share Transfer Agent, M/s. Bigshare Services Pvt. Ltd.
8th Apr 26
Impact Rating: 3
Kopran Limited clarified to the BSE about its significant trading volume increase. The company confirmed adherence to SEBI disclosure rules and stated no material information was withheld, attributing the surge to market activity.
24th Mar 26
Impact Rating: 5
Kopran Limited is closing its 'Trading Window' starting April 1, 2026. This closure will last until 48 hours post-announcement of the company's audited financial results for the fourth quarter and fiscal year ended March 31, 2026.